Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer
Nuvalent surged Tuesday after GSK said it would buy the Nasdaq-listed biotech for $10.6 billion, or $124 a share in cash. The stock shot up 38.9% to $122.93, almost reaching the offer price and trading like the day’s standard merger-arb play.